Use of Dipeptidyl peptidase-4 inhibitors is associated with lower risk of dementia in diabetic patients

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-E-038-Monday
• By: LIN, Yi-Ting (Kaohsiung Municipal Siaogang Hospital, Department of Family Medicine, Kaohsiung, China Taiwan)
• Co-author(s): Yi-Ting Lin: Department of Family Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan, Province of China;Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Province of China;Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China
  Ping-Hsun Wu: Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Province of China;Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China
  Yi-Hsin Yang: School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China
  Yuan-Han Yang: Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan, Province of China;Department of and Master’s Program in Neurology, Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China
  
• Abstract:

  Backgrounds

  Diabetes mellitus is associated with increased risk of dementia. Recent studies have shown that antidiabetic drugs have brain protection effect. However, rare study investigates the effect of Dipeptidyl peptidase-4 (DPP-4) inhibitors on dementia risk in patients with Diabetes Mellitus (DM).

  Aims

  To evaluate the association between the
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login